# Tailored Antiplatelet Therapy Following PCI

Study · id `cardio:ct-nct01742117` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01742117](<https://clinicaltrials.gov/study/NCT01742117>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01742117

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5276 participants.

## Technical summary

Registry record NCT01742117. Randomized; no masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2020-10-31 (actual). Results posted on 2021-11-09.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 5276 participants (enrolled count; ClinicalTrials.gov record NCT01742117, source copy `cardio:ctgov-nct01742117-2021-11-09`, retrieved 2026-10-26)
- Start date: 2013-05 (registry gives no type) (ClinicalTrials.gov record NCT01742117, source copy `cardio:ctgov-nct01742117-2021-11-09`, retrieved 2026-10-26)
- Primary completion: 2020-10-31 (actual) (ClinicalTrials.gov record NCT01742117, source copy `cardio:ctgov-nct01742117-2021-11-09`, retrieved 2026-10-26)
- Completion: 2020-10-31 (actual) (ClinicalTrials.gov record NCT01742117, source copy `cardio:ctgov-nct01742117-2021-11-09`, retrieved 2026-10-26)
- Results first posted: 2021-11-09 (ClinicalTrials.gov record NCT01742117, source copy `cardio:ctgov-nct01742117-2021-11-09`, retrieved 2026-10-26)
- Countries: United States; Canada; Mexico; South Korea (ClinicalTrials.gov record NCT01742117, source copy `cardio:ctgov-nct01742117-2021-11-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01742117-2021-11-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Tailored Antiplatelet Therapy Following PCI
- Acronym: TAILOR-PCI
- Condition: Coronary Artery Disease
- Condition: Acute Coronary Syndrome
- Condition: Stenosis
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Ticagrelor
- Lead sponsor: Mayo Clinic
- Lead sponsor class: OTHER
- Collaborator: Spartan Bioscience Inc.
- Collaborator class: INDUSTRY
- Collaborator: Applied Health Research Centre
- Collaborator class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Mayo Clinic (`cardio:org-mayo-clinic`)
- Registry lists this organization as a collaborator: Spartan Bioscience Inc. (`cardio:org-spartan-bioscience-inc`)
- Registry lists this organization as a collaborator: Applied Health Research Centre (`cardio:org-applied-health-research-centre`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial (`cardio:pubmed-32840598`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial (`cardio:pubmed-35699175`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention (`cardio:pubmed-37045502`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study (`cardio:pubmed-36445624`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI (`cardio:pubmed-42427167`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 01c6822511c3a5133370272a70de09ab5f68d8bab161ef48e72cb958d416dbe8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
